Additional file 1 of Breast cancer screening and early diagnosis in China: a systematic review and meta-analysis on 10.72 million women

Additional file 1: Table S1. The summary of detailed search keywords. Table S2. PRISMA checklist. Table S3. The pooled breast cancer detection rates in different subgroups of organized screening programs (China, 2010-2023). Table S4. The pooled early-stage (0–II) breast cancer detection rates in different subgroups of organized screening programs (China, 2010-2023). Table S5. The pooled proportion of early-stage (0–II) breast cancer in different subgroups of organized screening programs (China, 2010-2023). Figure S1. Forest plot of pooled breast cancer detection rate (China, 2010-2023) (A) opportunistic screening; (B) population screening. Figure S2. Forest plot of pooled early-stage (0–II) cancer detection rate (China, 2010-2023) (A) opportunistic screening; (B) population screening. Figure S3. Forest plot of pooled the proportion of early-stage (0–II) cancer (China, 2010-2023) (A) opportunistic screening; (B) organized screening

Additional file 6: of Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Figure S6. Hakai promotes BEL7402 cells invasion and growth. (A) Representative images and quantification of invasion in GFP-tagged Hakai-overexpressing BEL7402 cells by adenovirus. Scale bar = 200 μm. (B) Analysis of the ability of Hakai-overexpressing BEL7402 cells by adenovirus to form colonies. Data are presented as Mean ± SEM from three independent experiments (**p < 0.01, ***p < 0.001). (JPG 146 kb

Additional file 4: of Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Figure S4. Hakai mediates Ajuba degradation via neddylation. (A) Immunoblot analysis and quantification of the half-life of Ajuba in the presence of cycloheximide (CHX, 80 μg/ml), and in the presence or absence of MLN4924 (5 μM) in BEL7402 and HepG2 cells. GAPDH was used as a loading control. (B) Ubiquitination (Ub) assay of Ajuba in 293 T cells transfected with the indicated plasmids. (C) Neddylation assay of Ajuba in 293 T cells transfected with the indicated plasmids. IB, immnoblot. IP, immunoprecipitation. WCL, Whole-cell lysates. (JPG 103 kb

Additional file 1: of Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Figure S1. The regulation of β-Catenin and cell growth in HCC cells. (A, B) HCC cells were transfected with specific siRNAs to silence GSK3β protein in Ajuba-depleted HCC cell lines. The expression of GSK3β, Ajuba, CyclinD1 and GAPDH were tested by immunoblot assay (A). β-Catenin translocation were tested by confocal assay, Scale bar = 25 μm (B). (C, D) HCC cells were transfected with specific siRNAs to silence β-Catenin protein in Ajuba-depleted HCC cell lines. The expression of β-Catenin, Ajuba, CyclinD1 and GAPDH were tested by immunoblot assay (C). Cell growth was tested by colony formation (D). (E) HCC cells were transfected with specific siRNAs to silence YAP protein in Ajuba-depleted HCC cell lines. Cell growth was tested by colony formation. Data are presented as Mean ± SEM from three independent experiments (***p < 0.001). (JPG 515 kb

Additional file 5: of Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Figure S5. Ajuba knockdown-mediated β-catenin translocation into nucleus is not dependent on Hakai. (A, B) HepG2 cells were transfected with specific siRNAs to silence Ajuba protein in Hakai-depleted HepG2 cells. β-catenin translocation were tested by confocal assay, Scale bar = 25 μm (A). The expression of Ajuba, Hakai and β-catenin were tested by immunoblot assay, GAPDH was used as a loading control (B). (C) Immunoblot analysis of Ajuba and Hakai in BEL7402 and HepG2 cell lysis. GAPDH was used as a loading control. (JPG 617 kb

Additional file 2: of Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation

Figure S2. Ajuba was co-localized with Hakai in HepG2 cells. (A) HepG2 cells were co-transfected with Myc-Ajuba or Myc-Vector and GFP-Hakai for 24 h. Cells were analyzed for GFP-Hakai/Myc-Ajuba co-localization, Scale bar = 25 μm. (JPG 97 kb